Nanotechnology in cancer therapeutics: Bioconjugated nanoparticles for drug delivery

Molecular Cancer Therapeutics

Volumn 5, Issue 8, 2006, Pages 1909-1917

  Sinha, Rajni ^a   Kim, Gloria J ^b   Nie, Shuming ^a,b   Shin, Dong M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Emory University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAMPTOTHECIN; CETUXIMAB; CONTRAST MEDIUM; DAUNORUBICIN; DOXORUBICIN; DRUG RECEPTOR; ENDOSTATIN; GELATINASE A; GEMTUZUMAB OZOGAMICIN; GENEXOL PM; IPILIMUMAB; LECTIN; LIPOSOME; MACROGOL; MALEIMIDE DERIVATIVE; METHOTREXATE; MITOMYCIN; NANOPARTICLE; PACLITAXEL; PACLITAXEL POLIGLUMEX; PERTUZUMAB; POLYGLACTIN; PROTEIN P53; RITUXIMAB; SEMAXANIB; TACROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITRONECTIN RECEPTOR;

BIODEGRADABILITY; BIOENGINEERING; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER STAGING; CHEMICAL STRUCTURE; CLINICAL TRIAL; COLITIS; COLON CANCER; CONJUGATE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TARGETING; FATIGUE; GENE TARGETING; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; MICROENVIRONMENT; MYALGIA; NANOTECHNOLOGY; NAUSEA; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PARTICLE SIZE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; TUMOR VASCULARIZATION; VOMITING;

ANIMALS; ANTIGENS; CARBOHYDRATES; DRUG DELIVERY SYSTEMS; HUMANS; NANOSTRUCTURES; NANOTECHNOLOGY; NEOPLASMS; RECEPTORS, CELL SURFACE;

EID: 33748344520     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0141     Document Type: Review

References (69)

1. Alivisatos A. Perspectives on the physical chemistry of semiconductor nanocrystals. J Phys Chem 1996;100:13226-39.
2. Suntherland A. Quantum dots as luminescent probes in biological systems. Curr Opin Solid State Mater Sci 2002;6:36-370.
3. Perez E. American Pharmaceutical Partners announces presentation of Abraxane survival data. In: 22nd annual Miami Breast Cancer Conference; Miami, FL, 2005.
4. Williams J, Lansdown R, Sweitzer R, et al. Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors. J Control Release 2003;91:167-72.
5. Leroux J-C, Allemann E, De Jaeghere F, Duelker E, Gurny R. Biodegradable nanoparticles - From sustained release formulation to improved site specific drug delivery. J Control Release 1996;30:339-50.
6. Ringdorf H. Structure and properties of pharmacologically active polymers. J Polym Sci Symp 1975;51:135-53.
7. Maeda H, Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 1989;6:193-210.
8. Chari RV. Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Adv Drug Deliv Rev 1998;31:89-104.
9. Mansour AM, Drevs J, Esser N, et al. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albuminbinding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res 2003;63:4062-6.
10. Guo X, Szoka FC, Jr. Chemical approaches to triggerable lipid vesicles for drug and gene delivery. Acc Chem Res 2003;36:335-41.
11. Yockman JW, Maheshwari A, Han SO, Kim SW. Tumor regression by repeated intratumoral delivery of water soluble lipopolymers/p2CMVmIL-12 complexes. J Control Release 2003;87:177-86.
12. Nomura T, Saikawa A, Morita S, et al. Pharmacokinetic characteristics and therapeutic effects of mitomycin C-dextran conjugates after intratumoural injection. J Control Release 1998;52:239-52.
13. Prabha S, Labhasetwar V. Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells. Mol Pharmacol 2004;1:211-9.
14. Barker DD, Berk AJ. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 1987;156:107-21.
15. Khuri FR, Nemunaitis J, Ganly I, et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879-85.
16. Hecht JR, Bedford R, Abbruzzese JL, et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003;9:555-61.
17. Reid T, Galanis E, Abbruzzese J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl 1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002;62:6070-9.
18. Vasey PA, Shulman LN, Campos S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl 1520) given on days 1 through 5 every 3 weeks in patients with recurrent/ refractory epithelial ovarian cancer. J Clin Oncol 2002;20: 1562-9.
19. Galanis E, Okuno SH, Nascimento AG, et al. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther 2005;12:437-45.
20. Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J Pharmacol Exp Ther 2005; 315:196-202.
21. Raz A, Meromsky L, Lotan R. Differential expression of endogenous lectins on the surface of nontumorigenic, tumorigenic, and metastatic cells. Cancer Res 1986;46:3667-72.
22. Gorelik E, Galili U, Raz A. On the role of cell surface carbohydrates and their binding proteins (lectins) in tumor metastasis. Cancer Metastasis Rev 2001;20:245-77.
23. Yamazaki N, Kojima S, Bovin NV, et al. Endogenous lectins as targets for drug delivery. Adv Drug Deliv Rev 2000;43:225-44.
24. Olsnes S, Sandvig K. How protein toxins enter and kill cells. Cancer Treat Res 1988;37:39-73.
25. Kato Y, Seita T, Kuwabara T. Kinetic analysis of receptor-mediated endocytosis (RME) of proteins and peptides: use of RME as a drug delivery system. J Control Release 1996;39:191-200.
26. Yousaf N, Howard JC, Williams BD. Targeting behavior of rat monoclonal IgG antibodies in vivo: role of antibody isotype, specificity and the target cell antigen density. Eur J Immunol 1991;21:943-50.
27. 2b monoclonal antibodies. Eur J Immunol 1990;20:107-12.
28. Fuertges F, Abuchowski A. A clinical efficacy of poly(ethylene glycol)- modified proteins. J Control Release 1990;11:139-48.
29. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev 2001; 46:169-85.
30. Pechar M, Ulbrich K, Subr V, Seymour LW, Schacht EH. Poly(ethylene glycol) multiblock copolymer as a carrier of anti-cancer drug doxorubicin. Bioconjug Chem 2000;11:131-9.
31. Kratz F, Warneke A, Scheuermann K, et al. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives: improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared with that of the parent compound. J Med Chem 2002;25:5523-33.
32. Kratz F, Muller-Driver R, Hofmann I, Drevs J, Unger C. A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J Med Chem 2000;43:1253-6.
33. Vasey PA, Kaye SB, Morrison R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin): first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res 1999;5:83-94.
34. Hoes C, Potman, W, Heeswijk V. Optimization of macromolecular prodrugs of the antitumor metabolite antibiotic adriamycin. J Control Release 1985;2:205-13.
35. Hoes C, Grootoonk J, Duncan R. Biological properties of adriamycin-bound to biodegradable polymeric carriers. J Control Release 1993;23: 37-54.
36. Huriwitz E, Wilcheck M, Pitha J. Soluble macromolecules as carriers for daunorubicin. J Appl Biochem 1980;2:25-35.
37. Kato Y, Saito M, Fukushima H, Takeda Y, Hara T. Antitumor activity of 1-β-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative. Cancer Res 1984;44:25-30.
38. Batz H, Ringsdorf H, Ritter H. Pharmacologically active polymers. Cyclophosphamide and steroid hormone-containing polymers as potential anti-cancer compounds. Macromol Chem 1975;175:2229-39.
39. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003;2:347-60.
40. Wosikowski K, Biedermann E, Rattel B, et al. In vitro and in vivo antitumor activity of methotrexate conjugated to human serum albumin in human cancer cells. Clin Cancer Res 2003;9:1917-26.
41. Crown J, O'Leary M. The taxanes: an update. Lancet 2000;355: 1176-8.
42. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590-8.
43. Windebank AJ, Blexrud MD, de Groen PC. Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol Exp Ther 1994;268: 1051-6.
44. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8:1038-44.
45. Nyman D, Campbell K, Hersh. A phase I trial of ABI-007, nanoparticle paclitaxel, administered to patients with advanced non-hematological malignancies [abstract 2027)]. Oncol 2004;23:133.
46. Damascelli B, Cantu G, Mattavelli F, et al. Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): phase II study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. Cancer 2001;92:2592-602.
47. Kim SC, Kim DW, Shim YH, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 2001;72:191-202.
48. Kim TY, Kim DW, Chung JY, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004;10:3708-16.
49. Singer JW, Baker B, De Vries P, et al. Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv Exp Med Biol 2003;519:81-99.
50. Verrill M, Boddy A, Todd R, et al. Phase I trial pharmacokinetic (PK) study of CT-2103 given Q2 or Q2 weeks in patients with solid tumors. In: 39th Annual Meeting of the American Society of Clinical Oncology; Chicago (IL); 2003.
51. Burris H, Shipley D, Grecol A, Jones S, Bolton M. Phase I studies of CT-2103 in patients with non small lung cancer and with advanced malignancies. In: 12th Annual meeting of the European Cancer Conference; Copenhagen (Denmark); 2003.
52. Schulz J, Burris H, Redfern C, Bolton MG. Phase 2 study of CT-2103 in patients with colorectal cancer having recurrent disease after treatment with 5-fluorouracil-containing regimen. Proc Am Soc Clin Oncol 22: (Abstract #1137), 2003.
53. Robson L, Verrill M, Lind MJ, et al. A phase 2 study of CT-2103, a Poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks in patients with advanced breast cancer. Proc Am Soc Clin Oncol 22:42 (Abstract #169), 2003.
54. Backer MV, Backer JM. Targeting endothelial cells overexpressing VEGFR-2: selective toxicity of Shiga-like toxin-VEGF fusion proteins. Bioconjug Chem 2001;12:1066-73.
55. Mathias CJ, Hubers D, Low PS, Green MA. Synthesis of [{99m}Tc]DTPA-folate and its evaluation as a folate-receptor-targeted radiopharmaceutical. Bioconjug Chem 2000;11:253-7.
56. Vega J, Ke S, Fan Z, et al. Targeting doxorubicin to epidermal growth factor receptors by site-specific conjugation of C225 to poly(L-glutamic acid) through a polyethylene glycol spacer. Pharm Res 2003;20: 826-32.
57. Rowland GF, O'Neill GJ, Davies DA. Suppression of tumour growth in mice by a drug-antibody conjugate using a novel approach to linkage. Nature 1975;255:487-8.
58. Seymour LW, Ferry DR, Anderson D, et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 2002;20: 1668-76.
59. Garin-Chesa P, Campbell I, Saigo PE, et al. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol 1993; 142:557-67.
60. Reddy JA, Low PS. Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit Rev Ther Drug Carrier Syst 1998; 15:587-627.
61. Dauty E, Remy JS, Zuber G, Behr JP. Intracellular delivery of nanometric DNA particles via the folate receptor. Bioconjug Chem 2002; 13:831-9.
62. Paranjpe PV, Chen Y, Kholodovych V, et al. Tumor-targeted bioconjugate based delivery of camptothecin: design, synthesis and in vitro evaluation. J Control Release 2004;100:275-92.
63. Yoo HS, Park TG. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J Control Release 2004;100:247-56.
64. Ahmed SI, Thomas AL, Steward WP. Vascular endothelial growth factor (VEGF) inhibition by small molecules. J Chemother 2004;16 Suppl 4:59-63.
65. Chen QR, Zhang L, Gasper W, Mixson AJ. Targeting tumor angiogenesis with gene therapy. Mol Genet Metab 2001;74: 120-7.
66. Reynolds AR, Moein Moghimi S, Hodivala-Dilke K. Nanoparticle-mediated gene delivery to tumour neovasculature. Trends Mol Med 2003; 9:2-4.
67. Cleaver O, Melton DA. Endothelial signaling during development. Nat Med 2003;9:661-8.
68. Cheng S, Craig WS, Mullen D, et al. Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin αllbβ3 antagonists. J Med Chem 1994;37:1-8.
69. Bibby DC, Talmadge JE, Dalal MK, et al. Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice. Int J Pharm 2005;293:281-90.